Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) insider Dennis Karl Huang sold 389 shares of the stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $45.65, for a total value of $17,757.85. Following the completion of the sale, the insider now directly owns 75,314 shares in the company, valued at approximately $3,438,084.10. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Ultragenyx Pharmaceutical Stock Up 1.4 %
NASDAQ:RARE opened at $45.70 on Monday. The stock’s 50 day moving average price is $44.59 and its 200 day moving average price is $42.63. The company has a market capitalization of $3.21 billion, a PE ratio of -4.52 and a beta of 0.94. Ultragenyx Pharmaceutical Inc. has a 52-week low of $33.36 and a 52-week high of $85.53.
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) last released its quarterly earnings results on Thursday, February 16th. The biopharmaceutical company reported ($2.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.03) by ($0.13). Ultragenyx Pharmaceutical had a negative return on equity of 110.15% and a negative net margin of 194.71%. The firm had revenue of $103.35 million for the quarter, compared to analysts’ expectations of $105.11 million. During the same quarter in the prior year, the business earned ($1.79) EPS. The company’s quarterly revenue was up 23.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -7.62 EPS for the current fiscal year.
Institutional Trading of Ultragenyx Pharmaceutical
Analysts Set New Price Targets
A number of research firms have issued reports on RARE. Morgan Stanley reduced their price target on Ultragenyx Pharmaceutical from $100.00 to $95.00 and set an “overweight” rating on the stock in a research report on Friday, February 3rd. Credit Suisse Group reiterated an “outperform” rating and issued a $96.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Friday, February 17th. StockNews.com upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Thursday, February 23rd. Robert W. Baird increased their price objective on Ultragenyx Pharmaceutical from $50.00 to $57.00 and gave the company an “outperform” rating in a report on Friday, February 17th. Finally, HC Wainwright reiterated a “buy” rating and issued a $82.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Friday, December 30th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average price target of $89.47.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, engaged in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its products include Mepsevii and Crysvita. Mepsevii is an intravenous enzyme replacement therapy, which is used for the treatment of Mucopolysaccharidosis VII.
- Get a free copy of the StockNews.com research report on Ultragenyx Pharmaceutical (RARE)
- MarketBeat Week in Review – 2/27 – 3/3
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.